However, we did observe some tumour responses in this largely PD-L1-negative population, consistent with literature showing that patients whose disease is PD-L1 negative by IHC can still achieve clinical benefit with anti-PD-1/anti-PD-L1 therapies24. Here, CD274 is linked to neoplasm.